View allAllogeneic Cell SourcingCell Collection NetworkCell Therapy Supply ChainClinical Trials SupportIndustry StandardizationOutcomes ReportingSales Sheets
Sort by dateSort by name
DescendingAscending
Webinar

Strategies to Advance the Donor Selection Process for Cell Therapies to Improve Outcomes

Allogeneic Cell Sourcing

HLA matching in the development of leading-edge allogeneic therapeutics and cellular therapies—and hematopoietic stem cell transplantation (HSCT)—isn’t only about finding the best matches. It’s also about avoiding mismatches that could result in less optimal patient outcomes. During this on-demand webinar you’ll hear from industry experts about research identifying HLA-B mismatches that are most optimal and…

Webinar

Strategies to Relieve the Burden on Apheresis & Collection Centers

Cell Collection Network, Industry Standardization

As cell and gene therapies continue to progress at a rapid pace, apheresis and collection centers face the challenges of keeping up with demand, while maintaining high-quality levels. View this on-demand webinar for an in-depth discussion of standardization strategies that can bring efficiencies to the apheresis and collection infrastructure. Also included is a Q&A session…

Webinar

Streamlining Your Supply Chain to Support Next-Gen Therapies

Cell Therapy Supply Chain

As your cell and gene therapies move from early-phase clinical trials to commercialization, your supply chain complexity—and risk—increases. Anticipating setbacks and planning for their solution requires a specialized and collaborative approach with your supply chain partner. During this on-demand webinar, you’ll hear from industry experts who offer insights into developing a commercial supply chain for emerging autologous and allogeneic…

Case Study

The Challenge of Multiple Audits and Redundant Training

Cell Collection Network, Industry Standardization

As UCLA Health continues to participate in multiple CAR-T and other immunotherapy clinical trials, its apheresis unit and cell therapy lab continue to experience an increase in the need for their cell collection and processing services. Guest author, Heather Steinmetz, MPH, Quality Assurance Manager, UCLA Health Hematologic Malignancy/Stem Cell Transplant Program, shares some of the…

The EBMT/EHA CAR-T Cell Handbook

Cell Collection Network, Cell Therapy Supply Chain, Industry Standardization

A joint venture between the European Society of Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA), the CAR-T Cell Handbook offers clinical care applications for health care professionals in the EU that treat patients with CAR-T cell therapies. Download the guide for insights into many aspects of CAR-T cell therapies including: The…

Webinar

The role of AI in predicting stem cell donor availability

Clinical Trials Support, Outcomes Reporting

For allogeneic cell therapy developers, donor availability is a critical factor. Without a donor, there is no therapy. Watch this webinar to learn how groundbreaking AI-based approaches, like the NMDPSM Donor Readiness Score, can predict the availability of every registered donor and evaluate the predictive power during donor selection.  Our expert panel will explain how to: Predict an…

UK Review and Recommendations on the Procurement of Starting Materials by Apheresis for ATMP Manufacture

Cell Collection Network, Cell Therapy Supply Chain, Industry Standardization

To ensure safe, high-quality Advanced Therapy Medicinal Products (ATMPs) are delivered to patients, procurement activities must be standardized when possible. Standardization also supports efficiency and reduces the risk for error while meeting regulatory and accreditation requirements. Download the UK Review and Recommendations on the Procurement of Starting Materials by Apheresis for ATMP Manufacture for insights…

Webinar

Understanding Donor Characteristics to Improve Allogeneic Cell Therapy Outcomes for All

Allogeneic Cell Sourcing

Can donor-reported characteristics, like race and ethnicity, impact data quality for allogeneic cell therapies? That’s one of the questions our expert panelists will discuss during our upcoming webinar. You’ll walk away with a better understanding of:  Efficiencies in donor selection to reduce uncertainties about HLA matching and improve patient outcomes  HLA complexity in cell source selection  How machine…